Clinical Scorecard: Applying AMD Diagnostics

At a Glance

Key Highlights

• Latest diagnostic tools enable early and accurate detection of AMD at cellular and functional levels.
• Artificial intelligence enhances detection sensitivity, risk stratification, and supports home-monitoring.
• Functional tests like contrast sensitivity and dark adaptometry provide insight into real-world visual function and early disease biomarkers.

Guideline-Based Recommendations

Diagnosis

• Use advanced imaging technologies such as deformable mirror or wavefront sensors to visualize photoreceptors and RPE cells.
• Employ AI-based analysis of retinal images for early detection of drusen, pigmentary changes, geographic atrophy, and neovascularization.
• Perform fluorescein angiography (FA) and indocyanine green angiography (ICGA) to detect and characterize choroidal neovascularization.
• Incorporate functional tests including contrast sensitivity measurement and dark adaptometry to assess visual function and early AMD biomarkers.
• Consider genetic testing in high-risk individuals for risk assessment and clinical trial eligibility, though not routinely recommended.

Management

• Use diagnostic findings to inform patients about interventions and the importance of regular follow-up.
• Leverage AI tools for progression tracking and predictive modeling to guide treatment decisions.
• Integrate home-monitoring technologies supported by AI to enhance patient engagement and accessibility of care.

Monitoring & Follow-up

• Regularly monitor AMD progression using imaging and functional tests to detect subtle changes over time.
• Utilize AI-enabled platforms for real-time risk stratification and progression tracking.
• Encourage patient participation in home-monitoring to ensure consistent surveillance.

Risks

• Delayed detection may lead to irreversible vision loss; early and accurate diagnosis is critical.
• Genetic predisposition increases risk but does not guarantee disease development; counseling is important.
• Invasive tests like FA involve intravenous dye injection and require patient counseling about procedure.

Patient & Prescribing Data

Patients with early or suspected AMD and those at high genetic risk

Early detection through advanced diagnostics enables timely intervention and personalized monitoring strategies, improving chances of preserving vision.

Clinical Best Practices

• Explain diagnostic procedures in patient-centered language to motivate active participation in care.
• Combine structural imaging with functional testing for comprehensive AMD assessment.
• Adopt AI technologies to enhance diagnostic accuracy and efficiency.
• Use genetic testing selectively in high-risk patients to inform monitoring and potential trial enrollment.
• Promote regular follow-up and home-monitoring to detect progression early and adjust management accordingly.

References

• Retinal imaging with deformable mirror or wavefront sensor
• Contrast sensitivity and real-world visual function
• Dark adaptometry as early biomarker of AMD
• Fluorescein angiography in neovascular AMD
• Genetic testing for AMD risk assessment
• Indocyanine green angiography for choroidal neovascularization